NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

30/07/2015 - 2 minutes

Just as Boehringer Ingelheim, Bayer HealthCare expands its cancer portfolio this week. The German company is inclined to shell out €190M for a drug that interacts with the peculiar metabolism of cancer cells. Its developer, Sprint Bioscience AB, is a Swedish company founded in 2009, from former members of AstraZeneca, Biovitrum, and Pharmacia.

Sprint Bioscience is a public company based in Stockholm, that specializes in drug discovery of cancer treatments followed by an early out-licensing. The company bets on a fast development, as its name implies, as well as novel mechanisms to fight a major concern in the cancer therapy: treatment-resistant cancer cells.

Therefore, it focuses on the tumor’s special metabolism. As a result of a tumor’s uncontrolled growth, cancer cells are very hungry. To provide an increased nutrition supply, they exhibit an altered metabolism of carbohydrates, nucleic acids, lipids, and proteins. These changes make the cells often resistant to conventional radiation- and chemotherapy. But they can also be used as specific targets for cancer treatments.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member